Generation of a ribozyme-adenoviral vector against K-ras mutant human lung cancer cells

Applied Biochemistry and Biotechnology - Part B Molecular Biotechnology

Volumn 15, Issue 1, 2000, Pages 39-49

  Zhang, Yu An ^b   Nemunaitis, John ^b   Tong, Alex W ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

Antisense; Gene therapy; Non small cell lung cancer; Ras oncogene; Ribozyme

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; BCR ABL PROTEIN; RIBOZYME; VIRUS VECTOR;

ADENOVIRUS; ARTICLE; CANCER CELL; CANCER INHIBITION; GENE INACTIVATION; GENE MUTATION; GENE THERAPY; HUMAN; HUMAN CELL; LUNG CANCER; LUNG NON SMALL CELL CANCER; ONCOGENE C FOS; ONCOGENE H RAS; ONCOGENE K RAS;

EID: 0002431435     PISSN: 10736085     EISSN: None     Source Type: Journal    
DOI: 10.1385/MB:15:1:39     Document Type: Article

References (41)

1. 1. Rodenhuis, S. (1996) RAS oncogenes and human lung cancer in Lung Cancer: Principles and Practice (Pass H.I., Mitchell J.B., Johnson D.H., Turrisi AT. eds.), Lippincott-Raven, Philadelphia, PA, pp73-82.
2. 2. McCormick, F. (1993) Signal transduction: How receptors turn ras on. Nature 363, 15-16.
3. 3. Sun, J., Qian, Y., Hamilton, A.D., and Sebti, S.M. (1995) Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-ras mutation and p53 deletion. Cancer Res. 55, 4243-4247.
4. 4 Campbell, S.L., Khosravi-Far, R., Rossman, K.L., Clark, G.J., and Der, C.J. (1998) Increasing complexity of Ras signaling. Oncogene 17, 1395-1413.
5. 5. Zohn, I.M., Campbell, S.L., Khosravi-Far, R., Rossman, K.L., and Der, C.J. (1998) Rho family proteins and Ras transformation: the RHOad less traveled gets congested. Oncogene 17, 1415-1438.
6. 6. Downward, J. (1998) Ras signalling and apoptosis. Curr. Opin. Genet. Dev. 8, 49-54.
7. 7. Chou, C.C. and Yung, B.Y. (1997) Antiapoptotic effect of ras in the apoptosis induced by serum deprivation and exposure to actinomycin D. Naunyn-Schmiedebergs Arch. of Pharmacol. 355, 177-182.
8. 8. Ward, R.L., Todd, A.V., Santiago, F., O'Connor, T., and Hawkins, N. J. (1997) Activation of the K-ras oncogene in colorectal neoplasms is associated with decreased apoptosis. Cancer 79, 1106-1113.
9. 9. Irani, K., Xia, Y., Zweier, J.L., Sollott, S.J., Der, C.J., Fearon, E.R., Sundaresan, M., Finkel, T., and Goldschmidt-Clermont, P.J. (1997) Mitogenic signaling mediated by oxidants in ras-transformed fibroblasts. Science 275, 1649-1652.
10. 10. Rak, J., Filmus, J., Finkenzeller, G., Grugel, S., Marme, D., and Kerbel, R. S. (1995) Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev. 14, 263-277.
11. 11. Okada, F., Rak, J.W., Croix, B.S., Lieubeau, B., Kaya, M., Roncari, L., Shirasawa, S., Sasazuki, T., and Kerbel, R.S. (1998) Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc. Natl. Acad. Sci. USA. 95, 3609-3614.
12. 12. Lowy, D.R., and Willumsen, B.M. (1995) Rational cancer therapy. Nature Med. 1, 747-748.
13. 13. Cochet, O., Kenigsberg, M., Delumeau, I., Virone-Oddos, A., Multon, M. C., Fridman, W. H., Schweighoffer, F., Teillaud, J. L., and Tocque, B. (1998) Intracelluar expression of an antibody fragment neutralizing p21 ras promotes tumor regression. Cancer Res. 58, 1170-1176.
14. 14. Chang, E.H., Miller, P.S., Cushman, C., Devadas, K., Pirollo, K.F., Ts'o, P.O.,and Yu, Z.P. (1991) Antisense inhibition of ras p21 expression that is sensitive to a point mutation. Biochemistry 30, 8283-8286.
15. 15. Tidd, D.M. (1990) A potential role for antisense oligonucleotide analogues in the development of oncogene-targeted cancer chemotherapy. Anti-Cancer Res. 10, 1169-1182.
16. 16. Zhang, Y., Mukhopadhyay, T., Donehower, L.A., Georges, R.N., and Roth, J.A. (1993) Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Human Gene Ther. 4, 451-460.
17. 17. Georges, R.N., Mukhopadhyay, T., Zhang, Y., Yen, and N., Roth, J.A. (1993) Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. Cancer Res. 53, 1743-1746.
18. 18. Cech, T.R. (1990) Self-splicing of Group I introns. Ann. Rev. Biochem. 59, 543-568.
19. 19. Kijima, H., Ishida, H., Ohkawa, T., Kashani-Sabet, M., and Scanlon, K.J. (1995) Therapeutic applications of ribozymes. Pharmacol. Therap. 68, 247-267.
20. 20. Cech, T.R. and Uhlenbeck, O.C. (1994) Hammerhead nailed down. Nature, 372, 39-40.
21. 21. Koizumi, M., Kamiya, H., and Ohtsuka, E. (1992) Ribozyme designed to inhibit transformation of NIH3T3 cells by the activated c-Ha-ras gene. Gene 117, 179-184.
22. 22. Bennett, M.J., and Cullimore, J.V. (1992) Selective cleavage of closely related mRNAs by synthetic ribozymes. Nuc. Acids Res. 20, 831-837.
23. 23. Haseloff, J., and Gerlach, W.L. (1988) Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 334, 585-591.
24. 24. Ruffner, D.E., Stormo, G.D., and Uhlenbeck, O.C. (1990) Sequence requirements of the hammerhead RNA self-cleavage reaction. Biochemistry 29, 10,695-10,702.
25. 25. Funato, T., Shitara, T., Tone, T., Jiao, Lu, KashaniSabet, M., and Scanlon, K.J. (1994) Suppression of H-ras-mediated transformation in NIH3T3 cells by a ras ribozyme. Biochem. Pharmacol. 48, 1471-1475.
26. 26. Feng, M., Cabrera G., Desane, J., Scanlon, K.J., and Curiel, D.T. (1995) Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res. 55, 2024-2028.
27. 27. Kashani-Sabet, M., and Scanlon K.J. (1995) Application of ribozymes to cancer gene therapy. Cancer Gene Ther. 2, 213-223.
28. 28. Strauss, G.M., Kwiatkowski, D.J., Harpole, D.H., Lynch, T.J., Skarin, A.T., and Sugarbaker, D.J. (1995) Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung. J. Clin. Oncol. 13, 1265-1279.
29. 29. Zhang, Y., Nemunaitis, J., Mues, G., Scanlon, K.J., and Tong, A.W. (1996) In vitro suppression of human non-small cell lung cancer (NSCLC) cell growth by an anti-K-ras ribozyme (Abstract). FASEB J. 10, A1409.
30. 30. Nemunaitis, J., Klemow, S., Tong, A.,. Courtney, A., Johnston, W., Mack, M., Taylor, W., Solano, M., Stone, M., Mallams, J., and Mues, G. (1998) Prognostic value of ras mutations, ras oncoprotein and c-erb B-2 oncoprotein expression in adenocarcinoma of the lung. Am. J. Clin. Oncol. 21, 155-160.
31. 31. Ohta, Y., Kijima, H., Kashani-Sabet, M., and Scanlon, K.J. (1996) Suppression of the malignant phenotype of melanoma cells by anti-oncogene ribozymes. J. Invest. Dermatol. 106, 275-280.
32. 32. Kijima, H., Bouffard, D.Y., and Scanlon, K.J. (1996) Ribozyme-mediated reversal of human pancreatic carcinoma phenotype, in Proceedings of International Symposium on Bone Marrow Transplantation (Ikehara S. ed.), Verlag-Springer, Tokyo, pp.153-163.
33. 33. Campain, J.A., Matassa, A.A., Felgner, P.L., Barnhart, K.M., Curiel, D.T., and Harrison, G.S. (1998) Lipid- and adenoviral-mediated gene transfer into AIDS-Kaposi's sarcoma cell lines. Cancer Gene Ther. 5, 131-143.
34. 34. Felgner, P.L. (1997) Nonviral strategies for gene therapy. Sci. Am. 276, 102-106.
35. 35. Gunning, P., Leavitt, J., Muscat, G., Ng, S.Y., and Kedes, L. (1987) A human β-actin expression vector system directs high-level accumulation of antisense transcripts. Proc. Natl. Acad. Sci. USA 84, 4831-4835.
36. 36. Larrson, S., Hotchkiss, G., Andang, M., Nyholm, T., Inzunza, J., Jansoon, I., and Ahrlund-Richter, L. (1994) Reduced β2-microglobulin mRNA levels in transgenic mice expressing a designed hammerhead ribozyme. Nuclei Acids Res. 22, 2242-2248.
37. 37. Tong, A.W., Zhang, Y.A., Scanlon, K.J., and Nemunaitis, J. (1998) Anti-tumorigenic effect of a recombinant anti-K-ras ribozyme adenoviral vector on human non-small cell lung cancer (NSCLC) xenografts. In Proceedings of the 7th International Conference on Gene Therapy of Cancer, San Diego, CA, 1998.
38. 38. Zhang, Y.A., Nemunaitis, J., Scanlon, K.J, and Tong A.W. (1999) Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice, submitted.
39. 39. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) DNA sequencing in, Molecular Cloning: A Laboratory Manual, 2nd ed., (Ford N., Nolan C., and Ferguson M. eds.) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp.13.42-13.77.
40. 40. Becker, T.C., Noel, R.J., Coats, W.S., Gomez-Foix, A.M., Alam, T., Gerard, R.D., and Newgard, C.B. (1994) Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol. 43, 161-189.
41. 41. Graham, F.L. and Prevec, L. (1991) Manipulation of adenovirus vectors in Methods in Molecular Biology, vol. 7: Gene Transfer and Expression Protocols, Murray E.G., ed. pp. 109-128. Humana, Totowa, NJ, pp. 109-128.